Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?

Yiyuan Li; Shen Lin; Lixian Zhong; Shaohong Luo; Xiaoting Huang; Xiaojia Huang; Liangliang Dong; Xiongwei Xu; Xiuhua Weng

doi:10.2217/pgs-2021-0061

Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?

Yiyuan Li, Shen Lin, Lixian Zhong, Shaohong Luo, Xiaoting Huang, Xiaojia Huang, Liangliang Dong, Xiongwei Xu, Xiuhua Weng

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Aim: To compare the cost-effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in BRCA1, BRCA2 or ATM from the US payer perspective. Methods: A Markov model was constructed to assess the quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios. Sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties. Results: The base-case result indicated that, for patients with specific gene mutations, olaparib gained 1.26 QALYs and USD$157,732 total cost. Compared with control treatment, the incremental cost-effectiveness ratio of olaparib was USD$248,248/QALY. The price of olaparib was the most influential parameter. Conclusion: Olaparib is not cost effective in comparison with control treatment in metastatic castration-resistant prostate cancer patients with specific gene mutations.

Original language	English (US)
Pages (from-to)	809-819
Number of pages	11
Journal	Pharmacogenomics
Volume	22
Issue number	13
DOIs	https://doi.org/10.2217/pgs-2021-0061
State	Published - Aug 2021

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2021-0061

Cite this

@article{70d760a1f7dd41ad9c2386985367dc0a,

title = "Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?",

abstract = "Aim: To compare the cost-effectiveness of olaparib versus control treatment in metastatic castration-resistant prostate cancer patients with at least one gene mutation in BRCA1, BRCA2 or ATM from the US payer perspective. Methods: A Markov model was constructed to assess the quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios. Sensitivity analyses and scenario analyses were conducted to explore the impact of uncertainties. Results: The base-case result indicated that, for patients with specific gene mutations, olaparib gained 1.26 QALYs and USD$157,732 total cost. Compared with control treatment, the incremental cost-effectiveness ratio of olaparib was USD$248,248/QALY. The price of olaparib was the most influential parameter. Conclusion: Olaparib is not cost effective in comparison with control treatment in metastatic castration-resistant prostate cancer patients with specific gene mutations.",

author = "Yiyuan Li and Shen Lin and Lixian Zhong and Shaohong Luo and Xiaoting Huang and Xiaojia Huang and Liangliang Dong and Xiongwei Xu and Xiuhua Weng",

note = "Funding Information: This work was supported by the National Natural Science Foundation of China (no. 81973473) and the Natural Science Foundation of Fujian Province (no. 2019J01446). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 ",

year = "2021",

month = aug,

doi = "10.2217/pgs-2021-0061",

language = "English (US)",

volume = "22",

pages = "809--819",

journal = "Pharmacogenomics",

issn = "1462-2416",